Oncogenic KRAS signalling in pancreatic cancer

Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

(2015) Laura Conradt et al.   NEOPLASIA

Exploiting inflammation for therapeutic gain in pancreatic cancer

(2013) C W Steele et al.   BRITISH JOURNAL OF CANCER

Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

(2013) Esther Castellano et al.   CANCER CELL

Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer

(2013) Stefan Eser et al.   CANCER CELL

The Epidemiology of Pancreatitis and Pancreatic Cancer

(2013) Dhiraj Yadav et al.   GASTROENTEROLOGY

Understanding pancreatic cancer genomes

(2013) Mark J. Cowley et al.   Journal of Hepato-Biliary-Pancreatic Sciences

MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance

(2013) Katarina Zmajkovicova et al.   MOLECULAR CELL

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

(2013) Jaekyoung Son et al.   NATURE

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

(2013) Gunther Zimmermann et al.   NATURE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS -Mutant Lung Cancer

(2013) Miriam Molina-Arcas et al.   Cancer Discovery

Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation

(2012) Qi Sun et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma

(2012) Carolina Navas et al.   CANCER CELL

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

(2012) Christine M. Ardito et al.   CANCER CELL

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia

(2012) Mitsuro Kanda et al.   GASTROENTEROLOGY

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

(2012) Meredith A. Collins et al.   JOURNAL OF CLINICAL INVESTIGATION

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

(2012) Andrew V. Biankin et al.   NATURE

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice

(2012) Meredith A. Collins et al.   PLoS One

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

(2012) T. Maurer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer

(2012) Sarat Chandarlapaty   Cancer Discovery

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

(2012) Eric A. Collisson et al.   Cancer Discovery

c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

(2011) Rafael B. Blasco et al.   CANCER CELL

Early Requirement of Rac1 in a Mouse Model of Pancreatic Cancer

(2011) Irina Heid et al.   GASTROENTEROLOGY

StellaTUM: current consensus and discussion on pancreatic stellate cell research

(2011) Mert Erkan et al.   GUT

Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues

(2011) Michaela Aichler et al.   JOURNAL OF PATHOLOGY

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network

(2011) Haoqiang Ying et al.   Cancer Discovery

C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D

(2011) Florian A. Karreth et al.   Cancer Discovery

Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling

(2010) Georg Feldmann et al.   CANCER RESEARCH

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors

(2008) B. Seidler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE